Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Deborah Hilliard"'
Autor:
Luc M. Van Bortel, John A. Wagner, Karen Snyder, T Laethem, Arthur J. Bergman, Rajesh Krishna, Kenneth C. Lasseter, Kevin Dykstra, Josee Cote, Jingjing Chen, Deborah Panebianco, Bo Jin, Amit Garg, Cynthia Chavez-Eng, Laura Archer, Keith Gottesdiener, Ryan Lutz, Nidal Al-Huniti, Pascale Van Hoydonck, Kristien Van Dyck, Deborah Hilliard
Publikováno v:
British Journal of Clinical Pharmacology. 68:535-545
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Inhibition of cholesteryl ester transfer protein (CETP) is considered a potential new mechanism for the treatment of dyslipidaemia. Whereas several studies have described the effects of the CETP inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2797d0332c3b1dd12aef6c671ea2e8d5
https://doi.org/10.1111/j.1365-2125.2009.03465.x
https://doi.org/10.1111/j.1365-2125.2009.03465.x
Autor:
Kevin Dykstra, Arthur J. Bergman, Keith Gottesdiener, T Laethem, Daniel M. Bloomfield, P Van Hoydonck, Karen Snyder, M Fallon, Nidal Al-Huniti, K Van Dyck, Ryan Lutz, John A. Wagner, Bo Jin, L M Van Bortel, Maria Gutierrez, Omar F Laterza, M De Smet, Joshua Chen, I.N. Gendrano, Josee Cote, Rajesh Krishna, Cynthia Chavez-Eng, Deborah Hilliard
Publikováno v:
Clinical Pharmacology & Therapeutics. 84:679-683
Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high-density lipoprotein (HDL) and triglycerides to apolipoprotein B–containing lipoproteins, especially very low–density l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056fbe406c24fe12dca69bd8a46d2632
https://doi.org/10.1038/clpt.2008.109
https://doi.org/10.1038/clpt.2008.109
Autor:
Deborah Hilliard, Jules I. Schwartz, Derek L Chappell, Karen Snyder, Omar F Laterza, Patrick Larson, Jutta Miller, Mary Flynn, John A. Wagner, Jane Royalty, Aimee Dallob, Paul F. Cavanaugh
Publikováno v:
The Journal of Clinical Pharmacology. 48:745-754
We determined cyclo-oxygenase-1 and cyclo-oxygenase-2 inhibition in healthy middle-aged subjects (41-65 years) randomly assigned to four 7-day treatment sequences of etoricoxib 90 mg every day, celecoxib 200 mg twice a day, diclofenac 75 mg twice a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cb6ad034ecc121a79249ee904f1db4
https://doi.org/10.1177/0091270008317590
https://doi.org/10.1177/0091270008317590
Autor:
Kenneth C. Lasseter, David Hreniuk, Barry J. Gertz, Deborah Hilliard, Chau Thach, Jutta Miller, Jules I. Schwartz, Keith Gottesdiener, Karen Snyder
Publikováno v:
The Journal of Clinical Pharmacology. 47:1521-1531
This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily. Male and female subjects 60 to 81 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c84996274e4f98ffcce89ecdc932784
https://doi.org/10.1177/0091270007307878
https://doi.org/10.1177/0091270007307878
Autor:
Suzanne S. Eveland, Paul Zuck, Sheryl A. Hyland, Wesley Tanaka, Marc Ferrer, Berta Strulovici, Omar F Laterza, Ying Chen, Matt S. Anderson, Qiu Guo, John A. Wagner, Samuel D. Wright, Laurence B. Peterson, Gregory O'Donnell, Carl P. Sparrow, Denise P. Milot, Sylvie Jezequel-Sur, Deborah Hilliard
Publikováno v:
Analytical Biochemistry. 368:239-249
Cholesteryl ester transfer protein (CETP) is a serum component responsible for both cholesteryl ester and triglyceride trafficking between high-density lipoprotein (HDL) and the apolipoprotein B (apoB)-containing very low-density lipoprotein (VLDL) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::123d05e7f98c3e31163cda0f9a5ae4c8
https://doi.org/10.1016/j.ab.2007.06.003
https://doi.org/10.1016/j.ab.2007.06.003
Autor:
Mark Kipnes, Amy Qiu Wang, Deborah Hilliard, Kenneth C. Lasseter, John A. Wagner, Karen Snyder, Keith Gottesdiener, Wesley Tanaka, Bruno Dietrich, Jens J. Holst, Peng Zhao, Andreas Schrodter, Bart Keymeulen, Catherine Stevens, Carolyn F. Deacon, Kristien Van Dyck, Inge De Lepeleire, Caroline Cilissen, Arthur J. Bergman, Gary A. Herman, Wei Zeng, Marina De Smet, George Golor, Bingming Yi, Michael J. Davies, Paul Kotey, Michael Tanen
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:4612-4619
In response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released and modulate glycemic control. Normally these incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a6916322ba857ce28d9407665e271c
https://doi.org/10.1210/jc.2006-1009
https://doi.org/10.1210/jc.2006-1009
Autor:
Arthur J. Bergman, Amy Qiu Wang, Deborah Hilliard, Gregory A. Winchell, Gary A. Herman, Wei Zeng, Marina De Smet, Michael J. Davies, Kristien Van Dyck, Cathy Stevens, Wesley Tanaka, Karen Snyder, D.G. Musson, Keith Gottesdiener, John A. Wagner, Steven Ramael, Michael Tanen, Bingming Yi
Publikováno v:
Clinical Pharmacology & Therapeutics. 78:675-688
Background Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine]) is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-IV) cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa05b6d78789189f651ad1d5896a7fc
https://doi.org/10.1016/j.clpt.2005.09.002
https://doi.org/10.1016/j.clpt.2005.09.002
Autor:
Yi Lun, Kenneth J. Valenzano, Jessie Feng, Richie Khanna, Do Hung, Rebecca Soska, Kate Chang, Kimberly Pendino, Su Xu, Anju Nair, Michelle Frascella, Franklin K. Johnson, Russell Gotschall, Elfrida R. Benjamin, Anadina Garcia, Deborah Hilliard, Adriane Schilling
Publikováno v:
Molecular Genetics and Metabolism. 117:S66-S67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7ea8f0c02a4ba32e09f753715fb5696
https://doi.org/10.1016/j.ymgme.2015.12.318
https://doi.org/10.1016/j.ymgme.2015.12.318
Autor:
B Weiss, J Yao, Maria Gutierrez, R N K Snyder, Deborah Hilliard, Patrick Larson, Elizabeth Migoya, Nancy A. Thornberry, Jens J. Holst, Ranabir SinhaRoy, K A Pryor, John M. Amatruda, Michael Tanen, Lan Zhu, Gary A. Herman, Raynald Bergeron, D. E. Williams-Herman, John A. Wagner, Fang Liu, Guoqiang Jiang, Carolyn F. Deacon, Jutta Miller
Publikováno v:
Clinical pharmacology and therapeutics. 88(6)
The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active and inactive (or total) incretin plasma concentratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99a094e341137021bd919b76f7b169d
https://pubmed.ncbi.nlm.nih.gov/21048706
https://pubmed.ncbi.nlm.nih.gov/21048706
Autor:
Alan G. Meehan, Michael Tanen, Kenneth C. Lasseter, Cathy Stevens, Wesley Tanaka, Arthur J. Bergman, Amy Qiu Wang, Deborah Hilliard, Robert A. Blum, John A. Wagner, Fang Liu, Stacy C. Dilzer, Karen Snyder, Gary A. Herman, Wei Zeng, Li Chen
Publikováno v:
Journal of clinical pharmacology. 46(8)
Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. This multicenter, randomized, double-blind, placebo-controlled study examined the pharmacokinetic and ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::635a2cdb42aad87c673fda4292a74479
https://pubmed.ncbi.nlm.nih.gov/16855072
https://pubmed.ncbi.nlm.nih.gov/16855072